Company profile
Nanobac Pharmaceuticals, Incorporated
OTC: NNBP · Healthcare · Biotechnology
#1117 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
——FH —DQ —GM —SS 37
v0.1 · 5/100 weight · pillars only
↑ operating margin, listing tenure · ↓ workforce scale, net margin
Methodology →Revenue TTM
$17.6k
Rev growth YoY (TTM)
-92.2%
Net income (FY)
-$6.6M
Employees
1
as of 2026-08-29
Market cap
$25.0k
as of 2026-08-29
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$17.6k$17.6k2007
Net income-$6.6M-$6.6M2007
Operating income$4.9M$4.9M2007
Total assets$7.2M$7.2M2007
Liabilities$9.6M$9.6M2007
Equity-$2.4M-$2.4M2007
Revenue trend
FY1998 – FY2007 · USD
FY98
FY99
FY02
FY03
FY04
FY05
FY06
FY07
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Nanobac Pharmaceuticals, Incorporated’s revenue?
Nanobac Pharmaceuticals, Incorporated booked $17.6k in FY2007 revenue, contracting 92% year over year — slower than 90% of Healthcare companies we track, at a -37319.7% net margin.
Peers · Healthcare
South American Gold Corp.——THC Farmaceuticals, Inc.——Sector 10, Inc.——REMSleep Holdings, Inc.19DGemina Laboratories Ltd.——Upper Street Marketing Inc.——Neighbors
Hillsborough →Key facts
CEOJohn Stanton
SectorHealthcare
IndustryBiotechnology
HeadquartersTampa, FL
ExchangeOTC: NNBP
Employees1
IPO date1994-10-31
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.